Peptides researched for
NASH / MASLD (fatty liver)
Looking after a fatty liver
2 peptides · 4 studies
What people research this for
Fatty liver often has no symptoms, so people who find out they have it want to know how to protect their liver. One prescription peptide has trial data here. Another has indirect findings from a different group of patients.
Researched for
- Fatty liver
- Liver inflammation
- Liver health and weight
What the studies say so far
A 2021 mid-stage trial in the New England Journal of Medicine found that liver inflammation cleared up more often in people taking semaglutide than in people on placebo, without scarring getting worse. Stomach and gut side effects were common. Tesamorelin was studied in people with HIV who carry extra belly fat. When that fat went down, liver blood tests tended to look better, but those were side findings and not the main goal of the studies. Neither replaces care from a liver specialist.
Peptides studied
Each peptide below has been studied in this area. The label shows how far that research has gone.
Semaglutide
Tested in clinical trialsRandomized trial in people · 2 studies
Study note. NEJM phase 2 NASH trial: semaglutide increased NASH resolution without fibrosis worsening vs placebo; GI side effects were common.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. (opens in a new tab)
Newsome PN, Buchholtz K, Cusi K · The New England journal of medicine · 2021 · PubMed
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (opens in a new tab)
Wilding JPH, Batterham RL, Calanna S · N Engl J Med · 2021 · PubMed
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. (opens in a new tab)
Tesamorelin
Small early studies in peopleObservational study in people · 2 studies
Study note. Tesamorelin VAT reduction in HIV associates with improved liver enzymes and fat-quality metrics in secondary analyses.
- Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. (opens in a new tab)
Fourman LT, Czerwonka N, Feldpausch MN · AIDS (London, England) · 2017 · PubMed
- Tesamorelin improves fat quality independent of changes in fat quantity. (opens in a new tab)
Lake JE, La K, Erlandson KM · AIDS (London, England) · 2021 · PubMed
- Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. (opens in a new tab)
Look this up in the PeptIQ app
The app has the same research and sources, next to the tools you use to track your own protocol.
Related research
Insulin resistance / metabolic dysfunction
Weight, metabolism and hormones · 4 peptides
Obesity / weight management
Weight, metabolism and hormones · 4 peptides
HIV-associated lipodystrophy / visceral fat
Weight, metabolism and hormones · 1 peptide
Male hypogonadism / low testosterone
Weight, metabolism and hormones · 3 peptides
PCOS / ovarian metabolic
Weight, metabolism and hormones · 2 peptides
Sarcopenia / muscle loss
Recovery, joints and muscle · 3 peptides